CytoDyn (CytoDyn) Earnings per Share (Diluted) : $-0.05 (TTM As of Feb. 2024)

View and export this data going back to 2005. Start your Free Trial

What is CytoDyn Earnings per Share (Diluted)?

CytoDyn's Earnings per Share (Diluted) for the three months ended in Feb. 2024 was $-0.01. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Feb. 2024 was $-0.05.

CytoDyn's EPS (Basic) for the three months ended in Feb. 2024 was $-0.01. Its EPS (Basic) for the trailing twelve months (TTM) ended in Feb. 2024 was $-0.05.

CytoDyn's EPS without NRI for the three months ended in Feb. 2024 was $-0.01. Its EPS without NRI for the trailing twelve months (TTM) ended in Feb. 2024 was $-0.04.

During the past 3 years, the average EPS without NRIGrowth Rate was 29.20% per year. During the past 5 years, the average EPS without NRI Growth Rate was 13.10% per year. During the past 10 years, the average EPS without NRI Growth Rate was 6.50% per year.

During the past 13 years, CytoDyn's highest 3-Year average EPS without NRI Growth Rate was 29.20% per year. The lowest was -68.70% per year. And the median was 5.10% per year.

CytoDyn Earnings per Share (Diluted) Historical Data

The historical data trend for CytoDyn's Earnings per Share (Diluted) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CytoDyn Earnings per Share (Diluted) Chart

CytoDyn Annual Data

Trend

May14

May15

May16

May17

May18

May19

May20

May21

May22

May23

Earnings per Share (Diluted)

Get a 7-Day Free Trial

-0.21

-0.33

-0.30

-0.31

-0.10

CytoDyn Quarterly Data
	May19	Aug19	Nov19	Feb20	May20	Aug20	Nov20	Feb21	May21	Aug21	Nov21	Feb22	May22	Aug22	Nov22	Feb23	May23	Aug23	Nov23	Feb24
Earnings per Share (Diluted)	Get a 7-Day Free Trial															-0.02	-0.02	-0.01	-0.01	-0.01

Competitive Comparison of CytoDyn's Earnings per Share (Diluted)

For the Biotechnology subindustry, CytoDyn's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

CytoDyn's PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CytoDyn's PE Ratio distribution charts can be found below:

* The bar in red indicates where CytoDyn's PE Ratio falls into.

CytoDyn Earnings per Share (Diluted) Calculation

Earnings Per Share (EPS) is the amount of earnings per outstanding share of the company's stock. In calculating earnings per share, the dividends of preferred stocks need to subtracted from the total net income first.

CytoDyn's Earnings Per Share (Diluted) for the fiscal year that ended in May. 2023 is calculated as

Diluted Earnings Per Share (A: May. 2023 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Diluted Average)
	=	(-79.824	-	1.495)	/	836.528
	=	-0.10

CytoDyn's Earnings Per Share (Diluted) for the quarter that ended in Feb. 2024 is calculated as

Diluted Earnings Per Share (Q: Feb. 2024 )	=	(Net Income	-	Preferred Dividends	/	Shares Outstanding (Diluted Average)
	=	(-11.92	-	0.369)	/	982.209
	=	-0.01

Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Feb. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.05

Companies also reported diluted shares in their financial reports. Diluted shares include the shares of convertibles or warrants outstanding.

CytoDyn (OTCPK:CYDY) Earnings per Share (Diluted) Explanation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

CytoDyn Earnings per Share (Diluted) Related Terms

Thank you for viewing the detailed overview of CytoDyn's Earnings per Share (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.

CytoDyn (CytoDyn) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CytoDyn Inc (OTCPK:CYDY) » Definitions » Earnings per Share (Diluted)

Comparable Companies

Traded in Other Exchanges

296:Germany

Address

1111 Main Street, Suite 660, Vancouver, WA, USA, 98660

Website

https://www.cytodyn.com

CytoDyn Inc is a US-based clinical-stage biotechnology company that focuses on the clinical development and potential commercialization of humanized monoclonal antibodies to treat Human Immunodeficiency Virus (HIV) infection. The lead product candidate is PRO 140, which is a class of HIV therapy called entry inhibitors that block HIV from entering into and infecting certain cells. The company emphasizes exploring opportunities for clinical applications for PRO 140 involving the CCR5 (C-C chemokine receptor type 5) receptor, other than HIV-related treatments, such as inflammatory conditions, autoimmune diseases, and cancer.

Executives

Tyler Blok	officer: EVP of Legal Affairs	1111 MAIN STREET, SUITE 660, VANCOUVER WA 98660
Stephen M Simes	director
Ryan Dunlap	director	310 N. STATE STREET, SUITE 208, LAKE OSWEGO OR 97034
Arvin Cyrus Arman	officer: President	1111 MAIN STREET, SUITE 660, VANCOUVER WA 98660
Karen J Brunke	director	1111 MAIN STREET, SUITE 660, VANCOUVER WA 98660
Tanya Durkee Urbach	director	1111 MAIN STREET, SUITE 660, VANCOUVER WA 98660
Lishomwa C Ndhlovu	director	1111 MAIN STREET, SUITE 660, VANCOUVER WA 98660
Harish Seethamraju	director	1111 MAIN STREET, SUITE 660, VANCOUVER WA 98660
Alan P Timmins	director	1111 MAIN STREET, SUITE 600, VANCOUVER WA 98660
Gordon A Gardiner	director	1111 MAIN STREET, SUITE 660, VANCOUVER WA 98660
Samir Rashmikant Patel	director	1111 MAIN STREET, SUITE 660, VANCOUVER WA 98660
Antonio Migliarese	officer: Chief Financial Officer	1111 MAIN STREET, SUITE 660, VANCOUVER WA 98660
Chris P Recknor	officer: Chief Operating Officer	1111 MAIN STREET, SUITE 660, VANCOUVER WA 98660
Michael D. Mulholland	officer: CFO, Treasurer and Secretary	1111 MAIN STREET, SUITE 660, VANCOUVER WA 98660
Jordan G Naydenov	director	1111 MAIN STREET, SUITE 660, VANCOUVER WA 98660